Cargando…

Effective Use of PI3K and MEK Inhibitors to Treat Mutant K-Ras G12D and PIK3CA H1047R Murine Lung Cancers

Somatic mutations that activate phosphoinositide 3-kinase (PI3K) have been identified in the p110-α catalytic subunit (PIK3CA) 1. They are most frequently observed in two hotspots: the helical domain (E545K and E542K) and the kinase domain (H1047R). Although the PIK3CA mutants are transforming in vi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Engelman, Jeffrey A., Chen, Liang, Tan, Xiaohong, Crosby, Katherine, Guimaraes, Alexander R., Upadhyay, Rabi, Maira, Michel, McNamara, Kate, Perera, Samanthi A., Song, Youngchul, Chirieac, Lucian R., Kaur, Ramneet, Lightbown, Angela, Simendinger, Jessica, Li, Timothy, Padera, Robert F., García-Echeverría, Carlos, Weissleder, Ralph, Mahmood, Umar, Cantley, Lewis C., Wong, Kwok-Kin
Formato:	Texto
Lenguaje:	English
Publicado:	2008
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2683415/ https://www.ncbi.nlm.nih.gov/pubmed/19029981 http://dx.doi.org/10.1038/nm.1890

Ejemplares similares

PIK3CA(H1047R) and Her2 initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling
por: Cheng, Hailing, et al.
Publicado: (2015)

The PIK3CA H1047R Mutation Confers Resistance to BRAF and MEK Inhibitors in A375 Melanoma Cells through the Cross-Activation of MAPK and PI3K–Akt Pathways
por: Candido, Saverio, et al.
Publicado: (2022)

Identification of effective natural PIK3CA H1047R inhibitors by computational study
por: Liu, Naimeng, et al.
Publicado: (2021)

Expression of PIK3CA mutant E545K in the mammary gland induces heterogeneous tumors but is less potent than mutant H1047R
por: Meyer, D S, et al.
Publicado: (2013)

Investigating the Structure and Dynamics of the PIK3CA Wild-Type and H1047R Oncogenic Mutant
por: Gkeka, Paraskevi, et al.
Publicado: (2014)

Colon Cancer Tumorigenesis Initiated by the H1047R Mutant PI3K
por: Yueh, Alexander E., et al.
Publicado: (2016)

PIK3CA(H1047R)-induced paradoxical ERK activation results in resistance to BRAF(V600E) specific inhibitors in BRAF(V600E) PIK3CA(H1047R) double mutant thyroid tumors
por: Roelli, Matthias A., et al.
Publicado: (2017)

Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin
por: Cufí, Sílvia, et al.
Publicado: (2013)

Generation of a tree shrew breast cancer model using lentivirus expressing PIK3CA-H1047R
por: Zeng, Li, et al.
Publicado: (2023)

Conditional activation of Pik3ca(H1047R) in a knock-in mouse model promotes mammary tumorigenesis and emergence of mutations
por: Yuan, W, et al.
Publicado: (2013)

Recurrent PIK3CA H1047R-Mutated Congenital Infiltrative Facial Lipomatosis: A Case Report and Review of Literature
por: Oh, Kei Shing, et al.
Publicado: (2023)

Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers
por: Coussy, F., et al.
Publicado: (2020)

DMBA induced mouse mammary tumors display high incidence of activating Pik3ca(H1047) and loss of function Pten mutations
por: Abba, Martín C., et al.
Publicado: (2016)

Highly sensitive detection of the PIK3CA(H1047R) mutation in colorectal cancer using a novel PCR-RFLP method
por: Li, Wan-Ming, et al.
Publicado: (2016)

Treatment response to idelalisib in a patient with immunodeficiency-associated Burkitt lymphoma harboring a PIK3CA H1047R mutation
por: Bleckmann, Annalen, et al.
Publicado: (2020)

Protein and lipid kinase inhibitors as targeted anticancer agents of the Ras/Raf/MEK and PI3K/PKB pathways
por: García-Echeverría, Carlos
Publicado: (2008)

A novel hotspot specific isothermal amplification method for detection of the common PIK3CA p.H1047R breast cancer mutation
por: Kalofonou, Melpomeni, et al.
Publicado: (2020)

NODAL/TGFβ signalling mediates the self-sustained stemness induced by PIK3CA(H1047R) homozygosity in pluripotent stem cells
por: Madsen, Ralitsa R., et al.
Publicado: (2021)

Physiological Levels of Pik3ca (H1047R) Mutation in the Mouse Mammary Gland Results in Ductal Hyperplasia and Formation of ERα-Positive Tumors
por: Tikoo, Anjali, et al.
Publicado: (2012)

Somatic Mutation of PIK3CA (H1047R) Is a Common Driver Mutation Hotspot in Canine Mammary Tumors as Well as Human Breast Cancers
por: Lee, Kang-Hoon, et al.
Publicado: (2019)

K-RAS Mutant Pancreatic Tumors Show Higher Sensitivity to MEK than to PI3K Inhibition In Vivo
por: Hofmann, Irmgard, et al.
Publicado: (2012)

Structural Perturbations due to Mutation (H1047R) in Phosphoinositide-3-kinase (PI3Kα) and Its Involvement in Oncogenesis: An in Silico Insight
por: Sharma, Jatin, et al.
Publicado: (2019)

H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation via heregulin production and activation of HER3
por: Chakrabarty, Anindita, et al.
Publicado: (2010)

Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study
por: Yi, Zongbi, et al.
Publicado: (2019)

1047 proverbios del mundo : divertidos, sabios y profundos /
Publicado: (1997)

piK atom: Observation and lifetime measurement with DIRAC
por: Lanaro, A
Publicado: (2001)

S100a4 upregulation in Pik3caH1047R;Trp53R270H;MMTV-Cre-driven mammary tumors promotes metastasis
por: Yuan, Wenlin, et al.
Publicado: (2019)

Correction: Young Sik, K. Partial Derivative Approach to the Integral Transform for the Function Space in the Banach Algebra. Entropy 2020, 22, 1047
por: Sik, Kim Young
Publicado: (2020)

PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer
por: Nixon, Mellissa J., et al.
Publicado: (2019)

Pik3ip1 Modulates Cardiac Hypertrophy by Inhibiting PI3K Pathway
por: Song, Hong Ki, et al.
Publicado: (2015)

1047. Impact of Indication for Antibiotic Orders on Pharmacist Interventions
por: Scardina, Tonya, et al.
Publicado: (2019)

Calling large indels in 1047 Arabidopsis with IndelEnsembler
por: Liu, Dong-Xu, et al.
Publicado: (2021)

SG-APSIC1047: Patient instrument tracking system
por: Sirijindadirat, Nanthipha, et al.
Publicado: (2023)

Alternative dosing of dual PI3K and MEK inhibition in cancer therapy
por: Jokinen, Elina, et al.
Publicado: (2012)

PIK3CA mutations can initiate pancreatic tumorigenesis and are targetable with PI3K inhibitors
por: Payne, S N, et al.
Publicado: (2015)

eEF2K Activity Determines Synergy to Cotreatment of Cancer Cells With PI3K and MEK Inhibitors
por: Hijazi, Maruan, et al.
Publicado: (2022)

PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane–Based Neoadjuvant Chemotherapy
por: Guo, Sanxing, et al.
Publicado: (2020)

Targeting β-catenin overcomes MEK inhibition resistance in colon cancer with KRAS and PIK3CA mutations
por: Moon, Jai-Hee, et al.
Publicado: (2019)

The Mammalian Class 3 PI3K (PIK3C3) Is Required for Early Embryogenesis and Cell Proliferation
por: Zhou, Xiang, et al.
Publicado: (2011)

PIK3C3 regulates the expansion of liver CSCs and PIK3C3 inhibition counteracts liver cancer stem cell activity induced by PI3K inhibitor
por: Liu, Fengchao, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9ijvl71693jts6a3ejko1n5ukr